1.91
+1.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About XBiotech
From its filings with the US Securities and Exchange Commission
XBiotech is based in Austin, Texas and is incorporated in British Columbia, Canada. Its shares trade on Nasdaq under the ticker XBIT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $0.
XBiotech’s True Human™ monoclonal antibodies are derived from human donors that mount a natural human immune response. All other marketed antibody therapeutics are derived from animal immunization. It is intuitive that naturally occurring human antibodies have the potential to be safer, more effective and faster to develop than animal engineered counterparts. XBiotech has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. The Company has also developed manufacturing technology that reduces the cost and time to launch new product candidates. The Company designed and built a state-of-the-art research and manufacturing center at its Company’s 48 acre research campus in Austin, Texas. XBiotech is thus a fully integrated developer of biopharmaceuticals.
An area of medical focus for XBiotech are therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (ie. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. In many chronic (eg. arthritis) and acute injury scenarios (eg. stroke), IL-1a may mediate harmful disease-related activity.
Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Apr 2015
- Employees
- 63
- Head office
- 5217 WINNEBAGO LANE, AUSTIN, TX, 78744
- Incorporated in
- A1
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John SimardChairman of the Board, President, Chief Executive Officer, Founder, since 2005$6.2m
- Ms. Angela HuDirector of Finance$285,419
- Dr. Sushma ShivaswamyChief Scientific Officer$657,572
- Mr. Jan-Paul WaldinLead Independent Director$227,780
- Prof. Dr. Thomas KuendigIndependent Director
- Dr. Peter LibbyIndependent Director$193,295
- Dr. Tak MakIndependent Director
- Mr. Craig RademakerIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 48
- Social
- 63
- Governance
- 28
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- XBiotech Inc has a strong and experienced leadership team that brings expertise in the biotechnology industry. This enables the company to make sound strategic decisions and navigate the complex regulatory environment effectively.
- The company's proprietary True Human Antibody platform gives XBiotech a unique advantage in developing novel antibody therapeutics. This platform allows for the rapid discovery of promising antibody candidates to address unmet medical needs.
- XBiotech has a diverse pipeline of product candidates, targeting various diseases such as cancer and inflammatory disorders. This diversified portfolio mitigates the risks associated with relying on a single product for revenue generation.
Weaknesses
- One of the weaknesses of XBiotech is its heavy dependence on the success of its product candidates. Failure in clinical trials or regulatory challenges can significantly impact the company's financial performance.
- The company's limited financial resources pose a challenge in terms of funding the development of its product candidates, conducting clinical trials, and bringing them to market. This may require XBiotech to rely on partnerships or external funding sources, potentially diluting existing shareholders' ownership.
Opportunities
- XBiotech can take advantage of the growing demand for innovative biologic therapies. The increasing prevalence of diseases like cancer and autoimmune disorders creates significant market opportunities for the company's antibody therapeutics.
- Strategic collaborations or licensing agreements with larger pharmaceutical companies can provide XBiotech with access to additional resources, expertise, and distribution channels. This would accelerate the development and commercialization of its product candidates.
Threats
- Regulatory uncertainties and changes in government healthcare policies can pose threats to XBiotech's business. The company needs to stay updated with the evolving regulatory landscape and adapt its strategies accordingly.
- Competition within the biotechnology industry is intense, with numerous established companies and startups vying for market share. XBiotech must continuously innovate and differentiate itself to stay ahead of competitors and attract partnerships or investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.